Factor Xa Variants Modulating Hemostasis via Zymogen-Like Character
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for hemophilia, such as replacement of coagulation factors VIII or IX, often lead to the development of inhibitory antibodies, and alternative approaches like activated prothrombin complex concentrates or recombinant FVIIa have limitations including short half-life and potential thrombotic complications.
Innovation Solution
Development of Factor Xa variants with specific amino acid modifications at positions 16 and 17, which modulate hemostasis by promoting a 'zymogen-like' character, thereby extending half-life and reducing reactivity with inhibitors, allowing for effective thrombin generation and hemostasis without activating multiple upstream pathways.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If Factor Xa variants with amino acid modifications at positions 16 and 17 are developed to promote 'zymogen-like' character, then half-life is extended and reactivity with inhibitors is reduced, but thrombin generation capability must be maintained
Solution Approach 1:
The patent applies parameter changes by modifying specific amino acid residues at positions 16 and 17 of the Factor Xa molecule to create variants with altered properties. These substitutions change the molecular characteristics to achieve a zymogen-like state that extends half-life and reduces inhibitor reactivity while preserving thrombin generation capability
Solution Approach 2:
The invention inverts the typical active state of Factor Xa by promoting a zymogen-like character in the activated form. This unconventional approach creates an FXa variant that behaves more like its zymogen precursor, reducing reactivity with inhibitors while maintaining sufficient catalytic activity for thrombin generation
2Reliability
If alternative therapies like activated prothrombin complex concentrates or recombinant FVIIa are used to bypass the intrinsic pathway, then hemostasis can be achieved in inhibitor patients, but the half-life is short and thrombotic complications may occur
Solution Approach 1:
The patent modifies the kinetic and stability parameters of Factor Xa through amino acid substitutions, creating a variant with extended half-life compared to conventional bypassing agents. This parameter change allows for more sustained therapeutic effect without requiring frequent administration
Solution Approach 2:
The FXa variant serves as an intermediary that bridges the gap between the need for effective hemostasis and the desire for extended duration of action. By modifying Factor Xa's properties, it mediates between the conflicting requirements of immediate efficacy and prolonged effect
3Object-affected harmful factors
If Factor Xa variants with zymogen-like character are used to reduce reactivity with inhibitors, then safety is improved, but the ability to activate upstream pathways must be controlled
Solution Approach 1:
The patent applies local quality by making specific localized changes at positions 16 and 17 of the Factor Xa molecule. These localized amino acid substitutions create a zymogen-like character specifically at these regions, reducing inhibitor reactivity while preserving the overall catalytic function and controlled activation capability
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Factor X/Xa variants and methods of use thereof are disclosed.